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Abstract:  
 
Objective: Tumors and other disease complications of neurofibromatosis (NF) can cause pain 
and negatively affect physical functioning. To document the clinical benefit of treatment in NF 
trials targeting these manifestations, patient-reported outcomes (PROs) assessing pain and 
physical functioning should be included as study endpoints. Currently, there is no consensus on 
the selection and use of such measures in the NF population. This article presents the 
recommendations of the PRO group of the Response Evaluation in Neurofibromatosis and 
Schwannomatosis (REiNS) International Collaboration for assessing the domains of pain and 
physical functioning for NF clinical trials. 
 
Methods: The REiNS PRO group reviewed and rated existing PRO measures assessing pain 
intensity, pain interference, and physical functioning using their systematic method. Final 
recommendations are based primarily on 4 main criteria: patient characteristics, item content, 
psychometric properties, and feasibility for clinical trials. 
 
Results: The REiNS PRO group chose the Numeric Rating Scale–11 (≥8 years) to assess pain 
intensity, the Pain Interference Index (6–24 years) and the Patient-Reported Outcome 
Measurement Information System (PROMIS) Pain Interference Scale (≥18 years) to evaluate 
pain interference, and the PROMIS Physical Functioning Scale to measure upper extremity 
function and mobility (≥5 years) for NF clinical trials. 
 
Conclusions: The REiNS Collaboration currently recommends these PRO measures to assess 
the domains of pain and physical functioning for NF clinical trials; however, further research is 
needed to evaluate their use in individuals with NF. A final consensus recommendation for the 
pain interference measure will be disseminated in a future publication based on findings from 
additional published research. 
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ABSTRACT
Objective: Tumors and other disease complications of neurofibromatosis (NF) can cause pain and neg-
atively affect physical functioning. To document the clinical benefit of treatment in NF trials targeting
these manifestations, patient-reported outcomes (PROs) assessing pain and physical functioning
should be included as study endpoints. Currently, there is no consensus on the selection and use of
such measures in the NF population. This article presents the recommendations of the PRO group
of the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collab-
oration for assessing the domains of pain and physical functioning for NF clinical trials.
Methods: The REiNS PRO group reviewed and rated existing PROmeasures assessing pain inten-
sity, pain interference, and physical functioning using their systematic method. Final recommen-
dations are based primarily on 4 main criteria: patient characteristics, item content, psychometric
properties, and feasibility for clinical trials.
Results: The REiNS PRO group chose the Numeric Rating Scale–11 ($8 years) to assess pain
intensity, the Pain Interference Index (6–24 years) and the Patient-Reported Outcome Measure-
ment Information System (PROMIS) Pain Interference Scale ($18 years) to evaluate pain inter-
ference, and the PROMIS Physical Functioning Scale to measure upper extremity function and
mobility ($5 years) for NF clinical trials.
Conclusions: The REiNS Collaboration currently recommends these PRO measures to assess the
domains of pain and physical functioning for NF clinical trials; however, further research is needed
to evaluate their use in individuals with NF. A final consensus recommendation for the pain inter-
ference measure will be disseminated in a future publication based on findings from additional
published research. Neurology® 2016;87 (Suppl 1):S4–S12
GLOSSARY
CAT 5 computerized adaptive test; COA 5 clinical outcome assessment; FDA 5 Food and Drug Administration; IRT 5 Item
Response Theory; NF 5 neurofibromatosis; NF1 5 neurofibromatosis 1; NF2 5 neurofibromatosis 2; NRS-11 5 Numeric
Rating Scale–11; PII 5 Pain Interference Index; PRO 5 patient-reported outcome; PROMIS 5 Patient-Reported Outcome
Measurement Information System; PROMIS-PF 5 Patient-Reported Outcome Measurement Information System Physical
Functioning scale; PROMIS-PI 5 Patient-Reported Outcome Measurement Information System Pain Interference scale;
QOL 5 quality of life; REiNS 5 Response Evaluation in Neurofibromatosis and Schwannomatosis; SF 5 short forms;
SWN 5 schwannomatosis.
Neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis (SWN) are neuro-
genetic disorders that share a predisposition to develop multiple nerve sheath tumors. These tumors
may cause significant complications such as visual impairments, hearing loss, facial nerve palsy, air-
way constriction, and spinal cord compression.1 Generalized and focal orthopedic problems,
including spinal and skeletal abnormalities such as scoliosis, congenital bowing, tibial
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pseudoarthrosis, and chest wall malformations,
also may contribute to morbidity.2 Further-
more, chronic pain is common in children3,4
and adults5,6 with neurofibromatosis (NF) and
may be related to tumors, physical impairments,
and headaches.2,3,5,6 These complications of NF
can significantly affect physical functioning,
activities of daily living, and quality of life
(QOL).4,6
The number of clinical trials evaluating treat-
ments for tumors and other manifestations of
NF1, NF2, and SWN has increased over the
last several years. To assess clinical benefit
from the patients’ perspective in drug trials,
investigators have begun to incorporate patient-
reported outcome (PRO) measures as secondary
endpoints.7 Current behavioral intervention
studies focusing on reducing pain and its inter-
ference with everyday functioning use PROs as
primary endpoints.8 PRO measures also can fur-
ther define baseline disease characteristics7 and
document effects of drug toxicities.9 Regulatory
agencies in the United States and Europe recom-
mend including PRO tools in clinical trials to
systematically evaluate symptoms of interest10,11
as the data can provide complementary informa-
tion about the efficacy of a new treatment.10 To
support medical product approval and labeling
claims in the United States, PRO tools must
be qualified by the Food and Drug Adminis-
tration (FDA) as a clinical outcome assessment
(COA)12 and meet rigorous standards to be
used as trial endpoints.11 In meetings with
Response Evaluation in Neurofibromatosis
and Schwannomatosis (REiNS) members, the
FDA has indicated that COAs of pain and
physical functioning need to be incorporated
into trial design as coprimary or secondary
endpoints to document clinical benefit in addi-
tion to tumor reduction for NF trials seeking
drug approval.
Despite the increased interest in PROs,
challenges remain in using such measures of
pain and physical functioning in NF clinical
trials. First, the complications of NF are het-
erogeneous and vary widely in prevalence and
severity.1,13 Individuals often have multiple tu-
mors and complications, making it difficult to
differentiate changes in pain or functioning
related to one particular tumor type or compli-
cation being treated in a clinical trial. Pain may
be acute, episodic, or chronic, and vary in inten-
sity and location. Thus, when designing an NF
trial including pain PROs, researchers need to
consider the frequency of evaluations, length of
the response period (e.g., past 7 days), and how
to track the locations of target tumors or com-
plications in order to obtain reliable and valid
assessments of pain throughout the study. Accu-
rate recording of analgesic use also is required to
help distinguish changes in pain related to tumor
reduction due to the study drug from changes in
pain due to analgesics.14 In addition, NF com-
plications, such as plexiform neurofibromas3,5
and learning disabilities,15 are common in chil-
dren through adults. Therefore, PRO measures
used in NF trials must evaluate individuals across
a wide range of ages and ability levels. To be
feasible for multicenter and international studies,
PRO tools need to be relatively brief, easy to
administer, and available in different languages.
Finally, no measures currently are validated to
assess pain and physical functioning across the
lifespan in NF, and there is a lack of consensus
about how to assess PROs in NF clinical trials.
The US FDA and European regulatory agencies
have acknowledged the importance of developing
a common core language and methodology for
clinical trials evaluating new drugs that will per-
mit comparisons of PROs across treatments.10
To respond to these challenges and promote
consensus in the assessment of PROs in NF clin-
ical trials, the PRO group of the REiNS Inter-
national Collaboration is working to provide
guidance about appropriate PRO measures
and methodologies in 4 core domains (pain,
physical functioning, disease-specific QOL, and
general QOL) for use in NF clinical trials. The
PRO group’s first publication16 outlined their
goals and described the systematic process they
developed to review and choose PRO measures
using pain intensity as an example. This article
presents the current REiNS recommendations
for the domains of pain and physical function-
ing, specifically focusing on self-report measures
for ages 8 years and older and parent report
questionnaires for 5 years and older.
METHODS The group’s systematic method involves gathering
information from extensive literature reviews and rating existing
PROmeasures on 6 criteria, as previously described.16 PROmeasures
may be re-reviewed to consider new published data, and when scores
are close, the highest-rated measures are compared directly during the
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samemeeting. Of the 6 initial criteria, the group refined their focus to
the 4 it deemed most important when making the final selection of
a PRO measure17 for NF clinical trials. Thus, patient characteristics,
item content, psychometric properties, and feasibility for multicenter
trials were the primary criteria used to determine the recommendations
in the domains of pain and physical functioning. All the PROmeasures
reviewed for these domains are listed in table e-1 on the Neurology®
Web site at Neurology.org.
RESULTS Pain domain. Pain intensity recommendation.
The PRO group recommends the Numeric Rating
Scale–11 (NRS-11) as a self-report measure of pain
intensity (ages $8 years) for NF clinical trials, as
described and compared in detail with other tools in
our previous publication.16 On the NRS-11, respond-
ents are asked to circle the number from 0 (no pain) to
10 (e.g., worst pain imaginable) that best represents
their pain.18 The characteristics of the NRS-11 are
shown in table 1.
Pain interference. In the domain of pain interfer-
ence, our group initially identified 7 pain interference
scales to consider. Of these, 4 met basic criteria to be
suitable for use in NF clinical trials and were rated using
our systematic process. The top-rated measures were the
Pain Interference Index (PII),19 Patient-Reported
Outcome Measurement Information System Pain
Interference scale (PROMIS-PI),20 and Brief Pain
Inventory Pain Interference subscale.21 Our final
side-by-side comparison resulted in the highest overall
ratings, which were tied, for the PII and PROMIS-PI.
Table 2 presents the characteristics of the PII and
PROMIS-PI for each of the 4 main review criteria.
Pain Interference Index. The PII19,22 is a 6-item scale
that assesses the extent to which pain has interfered with
an individual’s daily activities in the past 7 days. Items
are rated on a 7-point Likert scale, and the total score is
the mean of the completed items. The PII is suitable for
NF clinical trials because it covers a wide age range,
assesses areas relevant for NF, and has parallel child
and adult self-report and parent proxy forms. Impor-
tantly for use in pediatric NF trials, the child and parent
forms demonstrate good reliability and validity in
NF1,19 yield high correlations between parent and child
scores,19 and show sensitivity to change after behavioral
interventions for chronic pain in children.8 While good
preliminary data exist in adults with NF1 (unpublished
data) and other conditions involving pain,23 more
research is needed before recommending the adult ver-
sion for NF trials.
Patient-Reported Outcome Measurement Information System
(PROMIS). PROMIS was created from an NIH-
sponsored initiative to develop standardized PRO
measures that can be compared across patient popula-
tions and studies in a variety of health domains
(http://www.nihpromis.org/). It utilizes Item Response
Theory (IRT), in which each item in a large item bank is
a measure of a latent trait that falls along a continuum. A
small subset of these items are administered as short
forms (SF) of various lengths (e.g., 8, 10, or 20 items)
or as a computerized adaptive test (CAT), which selects
the most relevant questions from an item bank based on
a person’s answers to previous questions, to produce
brief and precise outcome assessments.24,25 Items are
rated on a 5-point Likert scale, and the measures yield
standardized T scores. PROMIS scales are appropriate
for NF clinical trials because they assess relevant do-
mains in a wide age range, have good psychometric
properties, and are translated into multiple languages.
PROMIS-PI. The PROMIS-PI20 assesses the degree
to which pain has interfered with a patient’s ability to
complete daily activities over the past 7 days. This
Table 1 Characteristics of the Numeric Rating Scale–11 (NRS-11) for the 4 main review criteria
Criteria NRS-11 characteristics
Patient characteristics  Self-report form for $8 years18,40
 Preliminary validity data for children 6–7 years41
 No published data using the NRS-11 in neurofibromatosis to date16
Domains/item content  Assesses pain intensity
 Pain intensity rated from 0 (no pain) to 10 (worst pain you can imagine) over the past week
 Different instructions and pain descriptors used40
Psychometric data  Good test-retest reliability for children (mean difference 0.2; 95% CI 0.0–0.4)42 and adults (intraclass correlations 0.72–0.78)43
 Good construct validity supported by correlations with other pain intensity measures (e.g., NRS-11 and FPS-R, r 5 0.78)18
 Sensitive to change over time in children42 and adults43
Feasibility  Free, brief, simple to administer
 Can be administered by paper/pencil, verbally, or electronically
 Can modify descriptors and instructions
 Available in multiple languages and can be translated
Abbreviations: CI 5 confidence interval; FPS-R 5 Faces Pain Scale–Revised.
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scale has demonstrated feasibility and validity in
adults and youth with various medical conditions
and chronic pain.20,26,27 The PROMIS-PI also has been
shown to be responsive to changes in pain in a limited
number of clinical trials with adults28 but not yet with
children.29 Published studies using both the pediatric self-
report and parent-proxy pain interference scales currently
are scarce. The pediatric and parent forms are parallel and
general parent-child agreement is moderate.30 The item
content and response options of the adult form are not
consistent with the child/parent forms; thus, research is
needed to evaluate whether these scales can provide a reli-
able assessment across age ranges for longitudinal studies
involving children through adults. Studies investigating
the self-report and parent-proxy versions in NF, includ-
ing comparisons of CAT and SF administration in chil-
dren, also are required before our group can recommend
the PROMIS-PI for pediatric NF trials.
Pain interference recommendation. Since both of these
pain interference tools have strengths and weaknesses
for use in NF, the current REiNS recommendation is
to utilize the PII in clinical trials involving children to
young adults (6–24 years), the PROMIS-PI scale for
adult trials ($18 years), and when possible, both meas-
ures for trials enrolling children through adults. Since
there are limited publications using the PROMIS-PI in
longitudinal studies and none with the NF population to
date, the PRO group recommends administering the
longest PI SF available (8 items) or both the 8-item
SF and CAT in NF clinical trials to compare findings.
Our group will review newly published data in the
future to determine the one pain interference tool most
suitable for NF clinical trials.
Physical functioning domain. In the domain of physical
functioning, our group identified 6 PRO measures
Table 2 Characteristics of the Pain Interference Index (PII) and the Patient-Reported Outcome Measurement Information System Pain
Interference scale (PROMIS-PI) for the 4 main review criteria
Criteria PII characteristics PROMIS-PI characteristics
Patient characteristics  Self-report adult form $18 years  Self-report adult form $18 years
 Self-report pediatric form 6–24 years  Self-report pediatric form 8–18 years
 Parent proxy form 6–18 years  Parent proxy form 5–18 years
 Validation with children with chronic pain and with NF1  Validation with general population and several pediatric/adult disease
groups
Domains/item content  Items assess appropriate content for NF  Items assess appropriate content for NF
 Child/parent/adult items: school/work, leisure time, mood,
time with friends/family, physical activities, sleep
 Child/parent items: schoolwork, sleeping, standing, walking, running,
having fun, paying attention, feeling angry
 Parallel content and response format  Adult items include day-to-day and social activities, work around home,
family life, chores, fun things, and enjoyment of social activities and life
 Developed using Classical Test Theory  Not parallel content and response format between child/parent and adult
forms
 Developed using Item Response Theory
Psychometric data  Internal consistency in child self-report (Cronbach a 5 0.84)
and parent proxy (0.96)19 very good in NF1/cancer
 Internal consistency of the PI bank very good in adults
(Cronbach a 5 0.99)20 and children (0.87)35
 No test-retest reliability data to date  Good test-retest reliability in adults (intraclass correlations 5 0.83–
0.87)26; lower in children (0.62)35
 Good correlation between child self-report and parent proxy
scores (r 5 0.62, p , 0.0001)19 in NF1/cancer
 Moderate agreement between child and parent PI scores
(r 5 0.49)30
 Demonstrated construct validity based on correlation with
established pain measures (r 5 0.81) and differentiates
patients with varying levels of NF1 disease severity19
 Demonstrated construct validity with other PI scale (Spearman
r 5 0.90) and known groups validity in adults20
 Responsive to change in children and adolescents
after intervention8
 Known groups validity by disease severity for child self-report
PI scale27; no validity data for parent proxy to date
 Good preliminary psychometric data in adult patients23  Responsive to change in adults28; no changed detected in one pediatric
longitudinal study to date29
 SF and CAT highly correlated; CAT often more precise than SF
in adults36; SF generally more precise than CAT in one pediatric study35
Feasibility  Brief, easy to administer, free  Brief, easy to administer, free
 English and Swedish languages  Multiple languages
 Can modify items and format for NF  Can add items to customize for NF
 Can administer forms electronically  Can administer SF electronically; CAT administered electronically
Abbreviations: CAT 5 computerized adaptive testing; NF 5 neurofibromatosis; NF1 5 neurofibromatosis 1; SF 5 short form.
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appropriate for consideration; 5 met basic criteria to be
rated. Of these, the PROMIS Physical Functioning scale
(PROMIS-PF),25 Health Assessment Questionnaire,31
and Functional Disability Inventory32 were the top-
rated measures. From our final side-by-side comparison
of these 3 scales, the overall rating of the PROMIS-PF
for use in NF clinical trials was the highest. Table 3
presents the characteristics of the PROMIS-PF for each
of the 4 main review criteria.
PROMIS-PF. The PROMIS-PF scale measures the
perception of one’s capability of performing specific
physical activities. It includes items assessing upper
extremity function, mobility (lower extremity), and,
for adults, axial or head and neck function.25 The
PROMIS-PF demonstrates good reliability and con-
struct validity in adults and youth from the general
population and various disease groups.25–27,33–35 Adult
studies show that the IRT-based PROMIS-PF scales
reduce floor and ceiling effects,36 are more accurate
and efficient, decrease administration time, result in
greater responsiveness, and require smaller study sample
sizes than legacy PRO measures.36,37 Administration of
the 10-item PROMIS-PF CAT to adults resulted in an
efficient and precise measurement of physical function-
ing, which differentiated between age and disease
groups.36 However, in children with cerebral palsy,
the PROMIS Mobility CAT did not correlate with
performance measures or differentiate known mobility
groups.38 In clinical trials, the PROMIS-PF showed
sensitivity to change after spine augmentation in adults28
but not after surgery in children with cerebral palsy.29
Physical functioning recommendation. Although pub-
lished studies have not used the PROMIS-PF in
NF to date, the evaluation of both upper and lower
extremity function as well as the range, content, and
wording of the items are well-suited to assess the spec-
trum of complications affecting physical function in
NF. Therefore, the current REiNS recommendation is
Table 3 Characteristics of the Patient-Reported Outcome Measurement Information System Physical Functioning scale (PROMIS-PF) for the
4 main review criteria
Criteria PROMIS-PF characteristics
Patient
characteristics
 Self-report adult form $18 years
 Self-report pediatric form 8–17 years
 Parent proxy form 5–18 years
 Large validation samples including various disease groups
Domains/item
content
 Items assess appropriate content (upper extremity and mobility) for NF
 Measures both motor function and daily living activities
 Child and parent mobility items include doing sports, playing with other children, getting up from the floor, standing up, standing on tiptoes,
and walking upstairs; upper extremity items include buttoning shirt, opening a jar, opening school binder rings, pouring a drink, putting on
shoes, and using a key to unlock doors
 Adult items include how difficult it is to do chores, dress self including buttons/shoelaces, shampoo hair, wash/dry body, get on/off toilet, and
run a short distance; how their health limits physical tasks like bending or kneeling, walking, climbing stairs, carrying groceries, and doing
vigorous activities, like sports or lifting heavy objects
 Adult forms not parallel with child/parent forms; adult scale is unidimensional (physical functioning) and child/parent scales have 2 dimensions
(upper extremity and mobility)33
Psychometric data  Internal consistency excellent in adults with cancer (PF scale Cronbach a 5 0.92–0.96)34 and moderate in children (SF upper extremity 5
0.62; mobility 5 0.73)35
 Good test-retest reliability of PF scale in adults with osteoarthritis (intraclass correlations 5 0.92 CAT; 0.95 SF)26 and moderate in children
(SF upper extremity 5 0.66; mobility 5 0.77)35
 Demonstrated construct validity with established measures (all rs . 0.68) and known groups validity in adults with cancer34
 Known groups validity by disease severity for child upper extremity and mobility PF scales27; no validity data for parent proxy to date
 Good agreement between child self-report and parent proxy (upper extremity r 5 0.69; mobility r 5 0.63)44
 Sensitive to change after spine augmentation in adults28; no change after surgery in children with cerebral palsy29
 CAT version less accurate then the SF in children with cerebral palsy38; CAT was more precise than SF but CAT administered more items35
Feasibility  Brief, free, easy to administer
 Multiple languages for adult form; English and Spanish pediatric forms
 Can add items to customize the PF scale to NF
 Electronic administration of SF or CAT
 Easy to integrate testing with other PROMIS domains
Abbreviations: CAT 5 computerized adaptive testing; NF 5 neurofibromatosis; SF 5 short form.
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to use the longest PF SF that is feasible for a particular
study (e.g., 20-item SF was the most responsive in pop-
ulations with physical impairments)37 or the CAT in
adult studies. The CAT alone is not recommended
for pediatric studies at this time since it was less accurate
than the SF in children with functional limitations.38
When possible, giving both SF and CAT versions in
pediatric NF studies will allow comparisons between
the 2 versions to help refine these recommendations.
Recommendations for use of these measures for NF1, NF2,
and SWN.The above recommendations on pain inten-
sity, pain interference, and physical functioning PRO
measures (listed in table 4) apply to clinical trials
enrolling patients with NF1, NF2, or SWN. Each
measure was evaluated for its ability to capture rele-
vant changes in disease status regardless of the partic-
ular syndrome being studied (e.g., adequately
measuring pain interference from plexiform neurofi-
bromas in NF1 or from generalized chronic pain in
SWN). Since the NRS-11, PII, PROMIS-PI, and
PROMIS-PF assess generalized constructs rather than
disease-specific manifestations of pain and disability, they
are suited for a range of clinical trials in NF1, NF2, and
SWN. However, the patient population and objectives
of a particular clinical trial will dictate which of these
PRO measures are most appropriate and whether addi-
tional measures may be needed to capture the full range
of relevant PROs adequately. For example, a targeted
measure on swallowing or breathing may be warranted
for studies on plexiform tumors causing airway compres-
sion in NF1. Similarly, in trials for symptomatic vestib-
ular schwannomas in NF2, targeted questionnaires on
the effect of balance problems on physical activities or
the effect of hearing decline on communicative ability
may be warranted.
DISCUSSION PROs assessing pain and physical
functioning are critical for documenting the clinical
efficacy of treatments targeting manifestations of
NF1, NF2, and SWN. The REiNS International
Collaboration provides consensus recommendations
regarding PROs to the NF research community based
on extensive review of existing tools in these domains.
To assess pain intensity, the REiNS International
Collaboration recommends the NRS-11 as a brief, reli-
able, and valid self-report scale to assess pain intensity for
ages 8 years and older, as previously described.16 How-
ever, for NF clinical trials targeting tumor reduction,
research needs to explore modifications for assessing
tumor-specific pain and indicating the location of the
tumor pain being rated throughout a trial.
To assess pain interference, the current REiNS rec-
ommendation includes 2 measures until additional data
are published to determine the most appropriate one for
use inNF clinical trials across all age groups. At this time,
the REiNS group recommends the PII for pediatric
studies and the PROMIS-PI for adult trials. Both meas-
ures are recommended for NF studies including children
and adults so the data can be compared. The PII is valid
in children with NF1 and their parents19; however, there
currently are no published data in adults with NF1. The
PROMIS-PI20 is an IRT-based measure that has been
used in several published studies with adults, has excel-
lent feasibility, and has robust psychometric properties.
However, additional research is needed to examine the
use of the PROMIS-PI in children and parents, individ-
uals with NF, and CAT in longitudinal studies.
In the domain of physical functioning, the REiNS
Collaboration recommends the PROMIS-PF scale.25
Although relatively new, the PROMIS-PF was deemed
the most appropriate for NF clinical trials because it
evaluates both upper and lower extremity functioning,
consisting of a range of motor functions and daily living
activities that are important to assess in NF. This scale
should provide an efficient and precise PRO assessment
of physical functioning and require smaller sample
sizes,37 which is important for clinical trials of rare dis-
eases. However, CAT administration was not as accu-
rate as the SF in children with functional limitations so
both administration options need to be examined in the
NF population. Additional information also is needed
on the use of the pediatric scales over time.27
Table 4 Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) patient-reported outcome
recommendations for the pain and physical functioning domains in neurofibromatosis clinical trials
Trial age range Pain intensity Pain interference Physical functioning
Pediatric NRS-11 (SR $ 8) PII (SR 6–24; PP 6–18) PROMIS-PF (SR 8–17; PP 5–17)
Adult NRS-11 (SR $ 8) PROMIS-PI (SR $ 18) PROMIS-PF (SR $ 18)
Pediatric-adult NRS-11 (SR $ 8) PII (SR $ 6; PP 6–18) and
PROMIS-PI (SR $ 8; PP 5–17)a
PROMIS-PF (SR $ 8; PP 5–17)
Abbreviations: NRS-11 5 Numeric Rating Scale–11; PII 5 Pain Interference Index; PP 5 parent proxy; PROMIS-PF 5
Patient-Reported Outcome Measurement Information System Physical Functioning scale; PROMIS-PI 5 Patient-Reported
Outcome Measurement Information System Pain Interference scale; SR 5 self-report.
aCurrently, REiNS is recommending the PII for pediatric-only trials and the PROMIS-PI scale for adult-only trials. In clinical
trials enrolling both children and adults, it is recommended to give both the PII and PROMIS-PI until more data are
published and REiNS can make a final recommendation.
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Limitations. The continued work of the REiNS Col-
laboration and the broader scientific community will
be important in addressing the current limitations
associated with these recommendations. First is the
challenge of whether these PRO tools accurately
assess the specific types of pain and physical functions
being evaluated in clinical trials for individuals with
NF when multiple factors may contribute to their
pain experience or impact their daily functioning.
Another issue is the lack of data in NF1, NF2, and
SWN and whether the psychometric properties of the
scale in these conditions will be consistent with those
documented in the general population. Additionally,
no PRO tools to date have shown the ability to measure
pain and physical functioning adequately for all ages. In
particular, researchers need to address the evaluation
of these domains in children under 8 years old since
NF trials are enrolling these younger participants. This
challenge is reflected in our recommendation of 2 pain
interference scales, as currently there are insufficient pub-
lished data for establishing the validity of either measure
in children and adults with NF. Identifying the most
appropriate methods to assess children with significant
cognitive impairments also needs to be addressed. Our
group will update our recommendations in these specific
areas in future publications.
To address the limitations noted above, PRO
group members are using these recommended pain
and physical functioning measures in descriptive
studies and clinical trials with a wide age range of in-
dividuals who have all types of NF. Several of these
PROs have been accepted into the FDA’s Drug
Development Tool COA Qualification Program12
and are being further studied with both qualitative
and quantitative research methods11 to examine pos-
sible modifications and their use as NF clinical trial
endpoints. The PRO working group also plans to
form a subgroup that will focus on identifying meas-
ures to assess young children and individuals with
significant cognitive impairments. Finally, researchers
need to investigate the use of new methodologies in
NF clinical trials to improve PRO data, such as using
electronic administration to increase the accuracy and
speed of data collection.39
The REiNS PRO group is working to identify PRO
measures that can be used consistently as endpoints
across trials to assess clinical benefit of treatments to
reduce tumors or other disease manifestations in indi-
viduals with NF1, NF2, and SWN. The REiNS rec-
ommendations for PROs in the domains of pain and
physical functioning are presented with the understand-
ing that further evaluation of the measures is needed in
the NF population. Our group encourages researchers
to use these PRO measures in upcoming NF studies.
Final consensus recommendations regarding the one
specific pain interference measure and format of the
PROMIS-PF scales to use in NF clinical trials will be
disseminated in a future publication based on results
of additional published research.
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